Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
About Matinas BioPharma (MTNB)
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company dedicated to the development of innovative anti-infective therapies for orphan indications. Leveraging its proprietary lipid-crystal nano-particle cochleate technology, the company aims to transform the delivery and efficacy of existing drugs by enhancing their safety, tolerability, and oral bioavailability. This cutting-edge technology encapsulates active pharmaceutical ingredients into cochleates, providing a novel delivery method that reduces toxicity and improves patient compliance compared to traditional formulations.
Core Technology and Applications
The cornerstone of Matinas BioPharma's innovation lies in its lipid-crystal nano-particle cochleate technology. This platform is designed to encapsulate existing drugs, protecting them from degradation while enabling oral administration of compounds that traditionally require intravenous delivery. This approach holds significant promise for addressing unmet medical needs in the treatment of severe fungal and bacterial infections, particularly in patient populations with limited therapeutic options.
Key Product Candidates
- MAT2203: Matinas' lead drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum antifungal agent. Currently in Phase 2 clinical trials, MAT2203 is being developed for the treatment of invasive fungal infections, offering a less toxic and more patient-friendly alternative to traditional intravenous formulations.
- MAT2501: Another promising candidate, MAT2501, is an orally-administered, encochleated formulation of amikacin, a broad-spectrum aminoglycoside antibiotic. This drug is in Phase 1 development for the treatment of acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multidrug-resistant Gram-negative bacterial infections.
Market Position and Competitive Landscape
Matinas BioPharma operates within the highly competitive biopharmaceutical industry, specifically targeting the anti-infective segment. The company distinguishes itself through its proprietary cochleate technology, which addresses key limitations of existing therapies, such as toxicity and the need for intravenous administration. While competitors in this space include other biotech firms developing anti-infective drugs, Matinas' technology offers a unique value proposition by enabling oral delivery of traditionally injectable medications.
Challenges and Opportunities
As a clinical-stage company, Matinas BioPharma faces several challenges, including the need for successful clinical trial outcomes, regulatory approvals, and securing funding or partnerships for further development. However, the company's focus on orphan indications and its innovative delivery platform position it to potentially address significant unmet medical needs. The ability to repurpose existing drugs with enhanced safety and efficacy profiles also provides a strategic advantage in navigating the complex drug development landscape.
Conclusion
Matinas BioPharma is at the forefront of innovation in the anti-infective space, leveraging its lipid-crystal nano-particle cochleate technology to redefine drug delivery and efficacy. While still in the clinical stage, the company's focus on addressing critical gaps in the treatment of severe fungal and bacterial infections demonstrates its commitment to improving patient outcomes. With its unique technology and promising drug candidates, Matinas BioPharma holds potential as a key player in the biopharmaceutical industry.
Matinas BioPharma Holdings (MTNB) announced a conference call on May 12, 2022, at 8:30 AM ET to discuss Q1 2022 operational and financial results. The company focuses on innovative intracellular delivery technologies using its lipid nanocrystal platform. Key assets include MAT2203, an oral antifungal in Phase 2 trials, and MAT2501, an oral formulation for bacterial infections currently in Phase 1. Collaborations with leading firms like BioNTech and Gilead strengthen its pipeline. The webcast will be available on Matinas' website and archived for 90 days.
Matinas BioPharma (MTNB) announced that CEO Jerry Jabbour is set to present at the 12th Annual BioNJ BioPartnering Conference, occurring virtually from May 9-13, 2022. His presentation is scheduled for May 10, from 11:00 a.m. to 12:30 p.m. ET. The conference aims to foster collaboration in the biopharmaceutical sector, and the company will leverage the BioPartnering 1:1 feature for one-on-one meetings. Matinas BioPharma focuses on innovative intracellular delivery solutions using its lipid nanocrystal platform and is currently advancing several product candidates, including MAT2203 and MAT2501.
BioNTech and Matinas BioPharma have announced an exclusive research collaboration to enhance mRNA vaccine formulations using Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology. The partnership aims to explore innovative approaches, including potential oral vaccines. Matinas will receive an upfront access fee and further research funding from BioNTech. Discussions for a licensing agreement for the LNC technology have also begun. This collaboration is viewed as a significant validation for Matinas' delivery platform, potentially benefiting millions through improved vaccine delivery methods.
Matinas BioPharma (MTNB) announced that CEO Jerry Jabbour will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. ET. Investors can arrange virtual meetings through the conference coordinator. The presentation will be available via webcast and archived on the company’s website for 90 days. Matinas focuses on advancing its lipid nanocrystal technology for drug delivery, with ongoing clinical trials for MAT2203 and MAT2501, targeting fungal and bacterial infections, respectively.
Matinas BioPharma (NYSE: MTNB) announced that CEO Jerry Jabbour will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. Pre-recorded presentations will be available on-demand. The conference offers insights into Matinas' lipid nanocrystal (LNC) platform technology, which enhances intracellular drug delivery. The company is developing product candidates like MAT2203 for fungal infections and MAT2501 for bacterial infections, with ongoing clinical trials. For more details, visit Matinas' website.
Matinas BioPharma Holdings (MTNB) reported fourth quarter and full year 2021 results, highlighting a net loss of $6.7 million for Q4 and $23.7 million for the year. Enrollment in the EnACT trial's fourth cohort continues, with 15 patients enrolled so far, and topline data expected in Q3 2022. The company plans to expand the trial into a fifth cohort pending FDA approval. They ended 2021 with $49.6 million in cash, sufficient to fund operations into 2023. A new in vivo study for LNC-remdesivir will begin in March 2022, aiming for further advancements in nucleic acid delivery technology.
Matinas BioPharma Holdings (MTNB) will host a conference call on March 8, 2022, at 8:30 a.m. ET to discuss its Q4 and full-year 2021 financial results. Interested participants can call (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and use conference ID 13727084. The live audio webcast will be available on Matinas' website, with an archive lasting 90 days. The company focuses on its lipid nanocrystal (LNC) platform technology, aiming to enhance intracellular delivery of drugs, including MAT2203 and MAT2501, which target serious infections and diseases.
Matinas BioPharma (MTNB) recently announced a successful End of Phase 2 meeting with the FDA regarding its MAT2203 program, which aims to treat invasive fungal infections. The company reported a survival rate of 98% in patients using MAT2203 compared to 88% with standard treatments. MAT2203's NDA submission is anticipated for late 2023, pending additional data from an expanded clinical trial. Financially, Matinas ended 2021 with approximately $49.9 million, sufficient to support operations through 2023. Collaborations with NIAID and Genentech remain promising for continued development.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) will host a conference call and audio webcast on January 25, 2022, at 8:30 a.m. ET to discuss corporate updates and its 2022 business outlook. The call will include updates on ongoing programs and collaborations. Key product candidates include MAT2203, an oral formulation of amphotericin B in a Phase 2 study for cryptococcal meningitis, and MAT2501, in Phase 1 for NTM lung disease. LYPDISO™, an omega-3 therapy, is also under development. The call can be accessed via their website.
Matinas BioPharma Holdings, Inc. (MTNB) reported that the Data and Safety Monitoring Board (DSMB) has approved the progression to the fourth cohort of the EnACT trial, evaluating MAT2203 for cryptococcal meningitis. The third cohort demonstrated successful antifungal activity above the target threshold, maintaining a strong safety profile. Enrollment for 40 additional patients is anticipated to start in early Q1 2022. MAT2203 aims to be a first-line treatment option, potentially transforming the landscape for invasive fungal infections.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
What is Matinas BioPharma's primary focus?
What is cochleate technology?
What are Matinas BioPharma's key product candidates?
What differentiates Matinas BioPharma in the biopharmaceutical industry?
What challenges does Matinas BioPharma face?
What is MAT2203 used for?
What market need does MAT2501 address?
What is the significance of Matinas BioPharma's focus on orphan indications?
